{"id":"NCT03557307","sponsor":"AstraZeneca","briefTitle":"Study to Evaluate Efficacy and Safety of Benralizumab in Reducing Oral Corticosteroid Use in Adult Patients With Severe Asthma","officialTitle":"PONENTE: A Multicenter, Open-label, Phase 3b Efficacy and Safety Study of Benralizumab 30 mg Administered Subcutaneously to Reduce Oral Corticosteroid Use in Adult Patients With Severe Eosinophilic Asthma on High Dose Inhaled Corticosteroid Plus Long-acting Î²2 Agonist and Chronic Oral Corticosteroid Therapy","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2018-08-01","primaryCompletion":"2021-04-16","completion":"2022-03-24","firstPosted":"2018-06-15","resultsPosted":"2022-06-28","lastUpdate":"2023-06-06"},"enrollment":598,"design":{"allocation":"NON_RANDOMIZED","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Asthma"],"interventions":[{"type":"BIOLOGICAL","name":"Benralizumab","otherNames":[]}],"arms":[{"label":"Benralizumab","type":"EXPERIMENTAL"}],"summary":"This is a study designed to evaluate efficacy and safety of Benralizumab in reducing the Oral Corticosteroid (OCS) use in adult patients with severe asthma who are receiving OCS with or without additional asthma controller medications.","primaryOutcome":{"measure":"Patients Who Achieve 100% Reduction in Daily OCS Dose","timeFrame":"Baseline to end of OCS reduction phase, an average of approximately 200 days (The duration of the OCS reduction phase may vary based on asthma exacerbations, asthma worsening, HPA integrity , or other safety issues altering the OCS titration schedule.)","effectByArm":[{"arm":"Benra 30 mg","deltaMin":376,"sd":null}],"pValues":[{"comp":"OG000","p":null}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":144,"countries":["United States","Argentina","Belgium","Brazil","Canada","Colombia","Denmark","France","Germany","Italy","Mexico","Poland","Russia","Spain","Sweden","Taiwan","United Kingdom"]},"refs":{"pmids":["35896216","34619104","31579676"],"seeAlso":["https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217111&amp;parentIdentifier=D3250C00065&amp;attachmentIdentifier=ecf72bab-8195-4bbb-8146-15bdb632a43a&amp;fileName=d3250c00065-csp-v4_Redacted.pdf&amp;versionIdentifier=","https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217111&amp;parentIdentifier=D3250C00065&amp;attachmentIdentifier=c9237f6c-c83b-4019-8b75-9ed31b8fd5d0&amp;fileName=d3250c00065-sap-ed-4-Redacted.pdf&amp;versionIdentifier=","https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217111&amp;parentIdentifier=D3250C00065&amp;attachmentIdentifier=bf47c3cc-9aeb-4c0a-9026-61831356ca8c&amp;fileName=d3250c00065-study-synopsis_Redacted.pdf&amp;versionIdentifier="]},"adverseEventsSummary":{"seriousAny":{"events":89,"n":598},"commonTop":["Nasopharyngitis","Influenza like illness","Headache","Viral upper respiratory tract infection","Upper respiratory tract infection"]}}